Overview
Lobbying Costs
250,000€
Financial year: Jan 2018 - Dec 2018
Lobbyists (Full time equivalent)
0.5 Fte (1)
Lobbyists with EP accreditation
0
High-level Commission meetings
1
Lobbying Costs over the years
-
Info
Biogen Inc.
EU Transparency Register
966165310889-60 First registered on 26 Mar 2013
Goals / Remit
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is focused on advancing neuroscience research programs in Alzheimer’s disease and dementia, multiple sclerosis and neuroimmunology, movement disorders, neuromuscular disorders, pain, ophthalmology, neuropsychiatry, and acute neurology. Biogen also manufactures and commercializes biosimilars of advanced biologics.
Main EU files targeted
Biogen interacts with EU institutions and engages on issues relevant to Biogen and to the biopharmaceutical sector to develop a healthcare policy environment in which all patients have access to the medicines they need; pharmaceutical treatments are integrated into a continuum of care; financial returns attract investment; and the environment enables us to seek new innovative therapies and hopefully cures for this and future generations. We foster debates around the value of medical innovation including pharmaceutical incentives and rewards, sustainable healthcare systems, the future of neuroscience and patient access inequalities.
In 2018, we monitored several policy and legislative initiatives including the debates and initiatives on pricing & access and sustainable health systems and on pharmaceutical incentives & rewards; the implementation of EU Regulations incl. data protection and clinical trials; the European cooperation mechanisms on Health Technology Assessment such as EUnetHTA and the future of EU HTA collaboration; as well as policies and initiatives related to Off-Label Use, the prevention and early intervention in Chronic Diseases, Demographic change and healthy ageing, Alzheimer's disease, Competition in the pharmaceutical sector .Address
Head Office
225 Binney Street
Cambridge MA 02142
UNITED STATESEU Office
Park Lane G
Culliganlaan 2G
Diegem 1831
BELGIUM -
People
Total lobbyists declared
1
Employment time Lobbyists 50% 1 Lobbyists (Full time equivalent)
0.5
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
0 accreditations were / are live (in bold) for the selected state of 08 Apr 2019
Name Start date End Date Mr Alessandro Tempra 26 Nov 2021 26 Nov 2022 Mr Andrea Corazza 28 Sep 2021 30 Jul 2022 Mr Andrea Corazza 26 Feb 2020 26 Feb 2021 Ms Andreea Antonovici 17 Jan 2020 01 Feb 2021 Mr Alessandro Tempra 17 Jan 2020 01 Feb 2021 Ms Isabel KLINNERT 20 Jul 2017 15 Jul 2018 Emanuele DEGORTES 27 Jun 2017 19 Jun 2018 Ms Tresja Bolt 23 Jan 2017 23 Jan 2018 Mr Erwan Gicquel 03 Sep 2015 31 Aug 2016 Ms Danuta Rydlewska 03 Sep 2015 31 Aug 2016 Mr Erwan Gicquel 02 Aug 2014 31 Jul 2015 Ms Danuta Rydlewska 02 Aug 2014 31 Jul 2015 Mr Erwan Gicquel 07 Aug 2013 02 Aug 2014 Ms Danuta Rydlewska 07 Aug 2013 02 Aug 2014 Complementary Information
While several Biogen employees contribute to the company’s activities falling under the scope of the Transparency Register, only 1 Biogen employees spent more than 10% of their respective work time in 2018 on this. This person left the company in June 2018.
Person in charge of EU relations
Ms delphine Caroff (Corporate Affairs)
Person with legal responsibility
Mr Michel Vounatsos (CEO)
-
Categories
Category
II - In-house lobbyists and trade/business/professional associations
Subcategory
Companies & groups
-
Networking
Affiliation
In 2018 Biogen was a member of EFPIA, EuropaBio and Eucope.
Member organisations
None declared
-
Financial Data
Closed financial year
Jan 2018 - Dec 2018
Lobbying costs for closed financial year
250,000€
Other financial info
The estimated costs of Biogen activities for the year 2018 include staff costs based on the full-time equivalents (from january to june) already declared, payment to third parties (e.g. fees for consultants) and membership and related fees for joining relevant networks and structures (e.g. trade associations). This estimate follows and is consistent with the guidance provided by the European Federation of Pharmaceutical Industries and Associations (EFPIA).
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
None
Communication activities
not applicable
Other activities
None declared
Meetings
Meetings
1 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
-
Date 27 Nov 2015 Location Brussels Subject Biopharmaceutical industry's contribution to jobs and growth Cabinet Cabinet of Vice-President Jyrki Katainen Portfolio Jobs, Growth, Investment and Competitiveness Attending - Grzegorz Radziejewski (Cabinet member)
Other Lobbyists